Major Psychedelic Stocks Down This Week; Still Up Since End Of June

psychedelic stocks

There are 108 clinical-stage psychedelic drug stocks trading on North American stock exchanges (see here) of which 68 research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (see here) and 40 research the treatment of illnesses based on the use of THC marijuana. 

The 8 stocks in the munKNEE Psychedelic Compounds-Based Drug Stocks Index are those that have market caps in excess of $50M and they went DOWN 8.4% this week for the first time in 5 weeks (i.e. the end of June) but are still UP 45.3% since then albeit DOWN 34.4% YTD.

Below is how they performed this week, in descending order, along with their performances since the end of June:

  1. Mind Medicine (MNMD): UP 14.5% this week; UP 14.1% since the end of June
    • focused on discovering, developing, and deploying the next generation of psychedelic-inspired medicines and therapies to address addiction and mental illness development.
  2. Cybin (CYBN): UP 11.1% this week; UP 42.9% since the end of June
    • focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
  3. Zynerba (ZYNE): UP 7.4% this week; UP 14.9% since the end of June
    • focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery.
  4. Allied Corp. (ALID): UP 5.8% this week; UP 14.6% since the end of June
    • focused on the research, development, and production of cannabinoid health solutions in the United States and has a product in a Phase I clinical trial in Columbia for treating post-traumatic stress disorder.
  5. Atai (ATAI): UP 4.6% this week; UP 25.8% since the end of June
    • focused on acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.
  6. Seelos (SEEL): DOWN 5.0% this week; UP 39.7% since the end of June
    • focused on developing products that address significant unmet needs in the Central Nervous System disorders and other rare disorders.
  7. Compass Pathways (CMPS): DOWN 8.5% this week; UP 69.7% since the end of June
    • focused on the development of a new model of psilocybin therapy for people with treatment-resistant depression, in which psilocybin is administered in conjunction with psychological support.
  8. GH Research (GHRS): DOWN 15.6% this week; UP 33.6% since the end of June
    • focused on developing novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.

In total, the munKNEE Psychedelic Compounds-Based Drug Stock Index went DOWN 8.4% this week but has still gone UP 45.3% since the end of June.


More By This Author:

Upward Trend In Canadian Cannabis Stocks Continues
Cronos Group Q2 Net Revenue Loss Reduced By 38%
Acreage Holdings' Q2 Financial Report Shows Marked Improvement

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Or Sign in with